ARS Pharmaceuticals, Inc. - Common Stock (SPRY)

The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2025 financial results and business highlights.

Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States

$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024

neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children

Company to Host Conference Call on March 20 at 8:30 a.m. ET

Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of all patients and caregivers managing Type 1 allergic reactions, bringing the total number of formulary platforms covering neffy to 30

Oral presentation on an efficacy study conducted in Japanese patients comparing anaphylaxis symptoms during oral food challenge with neffy as the initial treatment compared to site historical data on intramuscular auto-injectors, antihistamines and inhalers; patients receiving neffy had lower symptom scores within 10 minutes, supporting neffy as a needle-free option for management of anaphylaxis

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the Oppenheimer 35th Annual Healthcare Conference being held virtually.

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine nasal spray) 2 mg for undesignated use meets applicable state law requirements

Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions

SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 in San Francisco.

Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies

Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy® (epinephrine nasal spray) 2mg for use in emergency treatment of allergic reactions including anaphylaxis

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive license agreement with ALK-Abelló to commercialize neffy® in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royaltiesWell-capitalized with $349.6 million in cash, cash equivalents and short-term investments on a pro forma basis, supporting an operating runway of at least three yearsCompany to host conference call and webcast today at 8:00 a.m. ET

Agreement leverages ALK’s global footprint in developing and commercializing innovative allergy products

Third Quarter Earnings Conference Call to be Held on November 13 at 8:00 a.m. ET

SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that seven abstracts will be featured tomorrow, Friday, October 25 at the 2024 ACAAI Annual Scientific Meeting taking place in Boston, Massachusetts. The posters highlight a wide range of studies focused on intranasal epinephrine administration, including cardiovascular safety, human factor study of carrying two devices at all times, and real-world administration data in pediatric patients.

Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 2024 Cantor Global Healthcare Conference being held September 17-19, 2024 in New York City.

If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children

Patients can request a prescription from their existing healthcare provider, or meet with a physician virtually, to request a prescription for neffy ahead of product availability expected by late September

EURneffy offers adults and children (≥30 kg) in Europe living with severe allergic reactions the first new delivery method for adrenaline in more than 30 years in the EU